Understand the source comparison
Libido Peptides 2026 Update: Peptide Comparison
This table compares the primary libido-enhancing peptides with meaningful research updates in 2026, focusing on mechanism, updated dosing ranges, and clinical considerations identified this year. PT-141 (Bremelanotide) MC3R/MC4R agonist in hypothalamus. Trigge
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares the primary libido-enhancing peptides with meaningful research updates in 2026, focusing on mechanism, updated dosing ranges, and clinical considerations identified this year.
- PT-141 (Bremelanotide)
- MC3R/MC4R agonist in hypothalamus. Triggers arousal independent of vascular function
- 1.75mg subcutaneous (vs standard 2.0mg) shows equivalent efficacy
- Nausea reduced from 31% to 18% at lower dose; onset 30–45 min optimal
- Best option for psychogenic sexual dysfunction; lower dose improves real-world adherence
- Kisspeptin-10
- Stimulates GnRH neurons. Upstream regulator of LH/FSH and testosterone production
- 0.24–0.48nmol/kg optimal; doses >0.6nmol/kg show diminished response
- Biphasic curve means 'more isn't better'; synergy with oxytocin analogues documented
- Ideal for hypogonadal arousal deficits; combination protocols show promise over monotherapy
- Melanotan II
- Broad melanocortin receptor agonist (MC1R/MC3R/MC4R/MC5R)
- Keep ≤500mcg per dose to avoid cardiovascular stimulation
- Transient hypertension and tachycardia in 22% at doses >500mcg
- Effective but requires cardiovascular monitoring; not suitable for individuals with pre-existing hypertension
- Oxytocin Analogues
- Central oxytocin receptor activation in limbic arousal circuits
- Carbetocin (longer half-life) studied at 100–200mcg intranasal
- Enhanced when paired with kisspeptin-10; minimal standalone libido effect
- Adjunct only. Works synergistically but lacks standalone arousal efficacy in most protocols